Catalent, Inc. (NYSE:CTLT) Shares Acquired by State Street Corp

State Street Corp increased its position in shares of Catalent, Inc. (NYSE:CTLT) by 1.5% during the third quarter, Holdings Channel.com reports. The fund owned 7,451,135 shares of the company’s stock after acquiring an additional 113,095 shares during the quarter. State Street Corp’s holdings in Catalent were worth $451,315,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CTLT. Brooklyn Investment Group acquired a new stake in shares of Catalent during the 3rd quarter valued at $31,000. Sentry Investment Management LLC purchased a new stake in shares of Catalent during the third quarter valued at $53,000. Longfellow Investment Management Co. LLC boosted its position in shares of Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after purchasing an additional 305 shares during the period. Thurston Springer Miller Herd & Titak Inc. raised its holdings in Catalent by 57.5% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after buying an additional 431 shares during the period. Finally, Intact Investment Management Inc. purchased a new stake in Catalent during the third quarter valued at about $73,000.

Catalent Trading Up 0.9 %

Catalent stock opened at $62.37 on Tuesday. Catalent, Inc. has a 12 month low of $36.74 and a 12 month high of $62.37. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The stock has a market cap of $11.32 billion, a P/E ratio of -27.60, a P/E/G ratio of 2.46 and a beta of 1.15. The company’s fifty day simple moving average is $60.10 and its 200-day simple moving average is $58.80.

Catalent (NYSE:CTLT) last issued its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.10) earnings per share. As a group, sell-side analysts forecast that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Insider Activity at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now directly owns 10,835 shares in the company, valued at $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Robert W. Baird reissued a “neutral” rating and set a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. Finally, StockNews.com cut Catalent from a “hold” rating to a “sell” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating and seven have given a hold rating to the company. Based on data from MarketBeat.com, Catalent has a consensus rating of “Hold” and a consensus target price of $63.40.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.